The Inhibitory Effect of Amoxapine on Cytochrome P450 Enzyme Activity in Human Liver Microsomes

Eriko Sakurai, Mariko Iwase, Norimitsu Kurata, Tomoko Nagai, Hayato Hirashima, Yuki Nishimura, and Hajime Yasuhara

Abstract: Amoxapine is a tricyclic antidepressant used for the treatment of psychotic depression. Psychotic depression is generally refractory to medical treatment and plural medicines are usually prescribed concurrently. The cytochrome P450 (CYP) enzyme has been implicated in the metabolism of several psychotropic drugs, and has clinical relevance relating to drug-drug interactions between psychotropic drugs and other common medicines. This study investigated the effects of amoxapine on the activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 using human liver microsomes. Amoxapine inhibited both CYP2D6 and CYP3A4 with apparent Ki values of 25.4 and 41.3 μM, respectively. The calculated Ki value for amoxapine was higher than the common therapeutic concentration range in plasma. Our study also revealed that inhibition of CYP2D6 and CYP3A4 enzyme activity by amoxapine is based on a competitive mechanism. Based on the Ki values observed in this study and the therapeutic amoxapine concentration in the blood, we conclude that amoxapine would not cause the severe drug-drug interaction mediated by CYP enzymes.

Key words: amoxapine, cytochrome P450, human liver microsomes, inhibition, psychotic depression

Introduction

Amoxapine is categorized as a second-generation tricyclic antidepressant (TCA). In several previous studies on the pharmacodynamic properties of amoxapine, potent noradrenaline reuptake inhibition, potent 5-HT2 receptor antagonism, and dopamine D2 receptor antagonism were reported. Based on this, amoxapine is prescribed for the treatment of psychomotor retardation and depressive mood. Amoxapine has antipsychotic action in addition to the antidepressant effect caused by the dopamine D2 receptor antagonism, and is therefore extremely effective for the treatment of psychotic depression.

Psychotic depression is the term used to indicate severe depression complicated by psychotic features. The diagnostic category for psychotic depression is severe depressive episodes with psychotic symptoms (DSM IV). For the subcategory of psychotic symptoms, the patient should present with delusion, hallucinations, psychomotor agitation and retardation.

Department of Second Pharmacology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
The treatment of psychotic depression is different from other depression. TCA mono-therapy such as amoxapine alone is usually recommended for mildly affected patients, while combination therapy such as TCA together with other antipsychotic agents are commonly applied for patients with severe symptoms\(^{10}\). However, in cases of symptomatic treatment for patients with complicated psychotic depression but without accompanying severe symptoms, combination therapies are also frequently required\(^{11}\). In addition, it was reported recently that combination therapy for the treatment of psychotic depression is more effective than TCA mono-therapy\(^{12}\). With the current trend of medication by using selective serotonin receptor antagonist (SSRI) and selective noradrenaline receptor antagonist (SNRI) for the treatment of psychotic depression, amoxapine remains one of the important antidepressant pharmacotherapies in the clinical setting.

Medication for patients with psychotic depression commonly involves multiple drugs used concurrently, including TCA, other antipsychotic drug and SSRI. TCA have been prescribed in the treatment of depression for a long time, and it is well known that metabolism of some of the TCA is mediated by the cytochrome P450 (CYP) enzyme\(^{13-19}\). In the current multi-drug therapies used for patients with psychotic depression, there are many reports of drug-drug interactions between TCA and the other drugs described above\(^{20, 21, 24}\). However, most of the reports describe the inhibition of TCA metabolism by the co-administrated medicine. The inhibitory potential of TCA on CYP-mediated drug metabolism has not been extensively described, and risk assessments for multiple drug therapy in these patients have not considered factors such as unexpected changes in pharmacokinetic parameters and/or pharmacodynamics of the drugs. Amoxapine is frequency used for the treatment of psychotic depression and it is also commonly prescribed to be used concurrently with other antipsychotic drugs. However, there is no data evaluating the effect of amoxapine on CYP enzyme-mediated drug metabolism. Such information is necessary to properly assess the therapy risks and therefore to avoid adverse reactions in patients being treated for psychotic depression.

This study aimed to assess the effect of amoxapine on five CYP enzymes (CYP1A2, 2C9, 2C19, 2D6 and 3A4), which are important clinically due to their roles in drug metabolism. In addition, the influence of amoxapine metabolites on these CYP enzymes was determined.

**Materials and Methods**

**Chemicals and reagents**

Amoxapine was purchased from ICN Co., Ltd. (Irvine, CA, U.S.A.). Bufuralol, 1'-hydroxybufuralol, S-warfarin, 7-hydroxywarfarin, 1'-hydroxymidazolam, ethoxyresorufin S-mephenytin and 4-hydroxymephenytoin were purchased from Daiichi Pure Chemicals Co., Ltd. (Tokyo). Resorfin was obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A). Midazolam was generously donated by Nippon Roche K.K. Inc (Osaka). \( \beta \)-nicotinamide adenine dinucleotide phosphate (NADPH), G-6-P and G-6-P DH were purchased from Oriental Yeast Co., Ltd. (Tokyo). All other chemicals and reagents used were of the highest commercially available quality.

**Enzyme sample**

Human liver microsomes (pooled fraction from 10 patients) were obtained from the Human and Animal Bridging Research Organization (Non-profit organization) (Lot NO.
Effect of Amoxapine on Cytochrome P450

HPLM-8). The study protocol was approved by the Ethics Committee of Showa University, School of Medicine.

Analytical procedure of CYP enzyme activity

The inhibitory effects of amoxapine on the metabolism of five different CYP isoform-specific substrates were studied: ethoxyresorufin O-deethylation for CYP1A2, S-warfarin 7-hydroxylation for CYP2C9, S-mephenytoin 4'-hydroxylation for CYP2C19, bufuralol 1'-hydroxylation for CYP2D6 and midazolam 1'-hydroxylation for CYP3A4.

Ethoxyresorufin O-deethylation activity

The incubation mixtures (final volume, 500 μl) consisting of a NADPH generating system (0.6 mM NADPH, 5 mM G-6-P and 0.5 U G-6-P DH), 200 μg of microsomal protein, 2 μM ethoxyresorufin and 5 mM MgCl₂ and with or without amoxapine in 128 mM potassium phosphate buffer (pH 7.4) were incubated at 37°C for 15 minutes. The enzymatic reaction was terminated by 2 mL of methanol on ice. The samples were centrifuged at 1,800 × g for 10 min. The resulting supernatant was analyzed by fluorescence spectrophotometer (F-2000, HITACHI Co., Ltd. Tokyo). Fluorescence detection was performed at wavelengths of 530 and 585 nm, excitation and emission, respectively. The enzyme activity was calculated from the resorufln formation rate from ethoxyresorufin.

S-warfarin 7-hydroxylation activity

The incubation mixtures (final volume, 250 μl) consisted of a NADPH generating system (1 mM NADPH, 8 mM G-6-P and 0.5U G-6-P DH), 200 μg of microsomal protein, 5 μM S-warfarin and 4 mM MgCl₂ and with or without amoxapine in 54 mM potassium phosphate buffer (pH 7.4). The mixture was incubated at 37°C for 30 minutes and enzymatic reaction was terminated by 10 μL of 60% perchloric acid on ice. The samples were centrifuged at 12,000 × g for 5 min and the resulting supernatant was applied onto an HPLC system. The separation of 7-hydroxywarfarin was performed using a CAPCELLPAK C18 SG120 (4.6 mm × 15 cm) ODS column (Shiseido Co., Tokyo), and elution was performed with 0.5% phosphoric acid : acetonitril (62 : 38). The flow rate of the mobile phase was 1.2 mL/min and 7-hydroxywarfarin was detected by a fluorescence detector at wavelengths 315 nm and 415 nm, excitation and emission, respectively. CYP2C9 activity was calculated from the 7-hydroxywarfarin formation rates.

S-mephenytoin 4'-hydroxylation activity

The incubation mixtures (final volume, 500 μl) consisting of a NADPH generating system (1 mM NADPH, 8 mM G-6-P and 0.5U G-6-P DH), 200 μg of microsomes, 100 μM S-mephenytoin and 4 mM MgCl₂ and with or without amoxapine in 80 mM potassium phosphate buffer (pH 7.4) were incubated at 37°C for 60 minutes. The enzymatic reaction was terminated by 200 μl of acetonitril on ice. Phenobarbital (0.1 μg) was spiked as an internal standard and the major metabolite, 4'-hydroxymephenytoin, was extracted with 3 mL of dichlomethane. The dichroloemthane extracts were evaporated under a steam of dry nitrogen gas at 35°C. The resulting residue was reconstituted with the mobile phase and applied onto an HPLC. The separation of 4'-hydroxymephenytoin was performed using a CAPCELLPAK C18 AG120 (4.6 mm × 25 cm) ODS column (Shiseido Co., Ltd., Tokyo).
The flow rate of the mobile phase was 1 ml/min and UV absorbance was monitored at 204 nm. The enzyme activity was calculated from the 4'-hydroxymephenitoin formation rates.

**Bufuralol 1'-hydroxylation activity**

The incubation mixtures (final volume, 150 μl) consisting of a NADPH generating system (1 mM NADPH, 8 mM G-6-P and 0.4U G-6-P DH), 15 μg of microsomal protein, 10 μM bufuralol and 500 μM MgCl₂ and with or without amoxapine in 90 mM sodium-potassium phosphate buffer (pH 7.4) was incubated at 37°C for 15 minutes. The enzymatic reaction was terminated by 15 μl of 60% perchloric acid on ice. The resulting samples were centrifuged at 12,000 × g for 5 min. The supernatant was applied onto an HPLC system. The separation of 1'-hydroxybufuralol was carried out using an CAPCELLPAK C18 SG120 (4.6 mm × 25 cm) ODS column (Shiseido Co., Ltd, Tokyo). Elution was performed with 20 mM NaClO₄ (pH2.5): acetonitrile (70:30). The flow rate of the mobile phase was 1 ml/min and 1'-hydroxybufuralol was detected by fluorometric detection wavelengths at 252 nm and 302 nm, excitation and emission, respectively. Enzyme activity was calculated from the 1'-hydroxybufuralol formation rates from bufuralol.

**Midazolam 1'-hydroxylation activity**

The incubation mixtures (final volume, 200 μl) consisting of a NADPH generating system (1 mM NADPH, 8 mM G-6-P and 0.5U G-6-P DH), 100 μg of microsomal protein, 10 μM midazolam and 4 mM MgCl₂ and with or without amoxapine in 80 mM potassium phosphate buffer (pH 7.4) were incubated at 37°C for 5 minutes. The enzymatic reaction was terminated by 200 μl of methanol-acetonitrile on ice (35:21). Nitrazemep (0.75 nmol) was spiked as an internal standard and the reaction mixture was centrifuged at 12,000 × g for 10 min. The resulting supernatant was applied onto an HPLC system. The separation of 1'-hydroxymidazolam was carried out using a CAPCELLPAK C18 SG120 (4.6 mm × 25 cm) ODS column (Shiseido Co., Ltd, Tokyo). Elution was performed with 10 mM potassium phosphate buffer (pH 7.4): methanol: acetonitrile (66:17:17). The flow rate of the mobile phase was 1 ml/min and UV absorbance was monitored at 220 nm. The enzyme activity was calculated from the 1'-hydroxymidazolam formation rates from midazolam.

**HPLC system**

HPLC analyses of extracts of microsomal incubations were performed using a JASCO HPLC system (JASCO, Tokyo) with an intelligent pump (880-PU), automatic sample injector (851-AS), degasser (880-50) and system controller (802-SC). Detection was carried out using an SPD-6A (Shimadzu Co., Kyoto) and L7485 (Hitachi Co., Ltd, Tokyo), UV-detector and fluorescence detector. Data calculation was performed on a C-R7A integrator (Shimadzu Co., Kyoto).

**IC50 determinations**

IC50 values of amoxapine on CYP enzymes were calculated by the concentration-inhibition relationship and determined graphically from a plot of % control activity against amoxapine concentration.
Effect of Amoxapine on Cytochrome P450

Determination of inhibition constant

Dixon plot analysis was employed to determine the inhibition constant (Ki value) of amoxapine on CYP2D6 and CYP3A4. Amoxapine was applied to the incubation mixture at a concentration of between 1 and 1000 µM as illustrated in Figures 2 and 3. Substrate concentrations for bufuralol and midazolam were 5, 10 and 20 µM.

Preincubation-dependent inhibition of amoxapine on CYP enzymes

To evaluate the inhibitory effect of amoxapine metabolites on CYP enzymes activity, a pre-incubation study was conducted. Amoxapine concentrations of 50 µM for CYP1A2, 2C9, 2C19, and 3A4, and 10 µM for CYP2D6, were used. Pre-incubations were carried out for 10 to 30 min, with or without the NADPH generating system, before commencement of each CYP-dependent enzyme reaction.

Results

Inhibitory effects of amoxapine on CYP enzyme activities in human liver microsomes

To evaluate the inhibitory potency of amoxapine on CYP enzymes, the concentration-inhibition relationship was examined. Amoxapine was a potent inhibitor of CYP2D6 and 3A4 activity with apparent IC50 values of 25.37 and 76.87 µM, respectively. In contrast, amoxapine demonstrated only a weak inhibitory effect on CYP2C9 and CYP2C19 enzyme with IC50 values of 236.69 and 148.40 µM, respectively. A negligible inhibitory effect was observed on CYP1A2 (Fig. 1).

Dixon plot analysis of the effect of amoxapine on CYP2D6 in human liver microsomes

Dixon Plot analysis was also performed to confirm the inhibitory potency and mechanism of action of amoxapine on CYP2D6 and CYP3A4. Amoxapine was a competitive inhibitor.
Fig. 2. Dixon plot analysis of amoxapine on CYP2D6 and CYP3A4 in human liver microsomes. The human liver microsomes were incubated with 5, 10, and 20 μM of bufuralol in CYP2D6 and midazolam in CYP3A4. Each data point represents the average of duplicate determinations. The apparent Ki value was calculated by using the linear regression analysis method.

of both CYP2D6- and CYP3A4-mediated enzyme reactions with calculated Ki values of 25.4 and 41.3 μM, respectively (Fig. 2).

Influence of pre-incubation with amoxapine on CYP enzyme activity in human liver microsomes

To evaluate the participation of amoxapine metabolites in the inhibition of CYP enzyme-mediated drug metabolism, pre-incubation studies were performed. However, no significant gain in the inhibitory potency of amoxapine was observed (Fig. 3).
Effect of Amoxapine on Cytochrome P450

Fig. 3. Influence of preincubation with amoxapine on CYP enzymes activity in human liver microsomes.

Amoxapine was preincubated for 30 min, with or without NADPH, prior to commencement of CYP-dependent enzyme reaction.

The final concentration of amoxapine in the incubation mixture was 50 \( \mu \text{M} \) in CYP1A2, CYP2C9, CYP2C19 and CYP3A4, and 10 \( \mu \text{M} \) in CYP2D6.

Each data point represents the average of duplicate determinations.

Discussion

In the present study, we investigated the inhibitory potency of amoxapine on the CYP enzymes, CYP1A2, 2C9, 2C19, 2D6 and 3A4. Competitive inhibition was observed with CYP2D6 and 3A4, while only a marginal effect was observed with CYP1A2, 2C9 and 2C19. In general, TCAs are mainly metabolized to N-demethylated and hydroxylated forms \(^{13-19}\). The hydroxylation reaction is mainly mediated by CYP2D6 \(^{13,14,17,19}\), and several CYPs are involved in the N-demethylation \(^{15,16,18,19}\). Venkatakrishnan et al. reported that nortriptyline, classified in the same TCA group as amoxapine, is metabolized to 10-hydroxynortriptyline by CYP2D6 with an apparent Km value of 2.1 \( \mu \text{M} \) and CYP3A4 with an apparent Km value of 37.4 \( \mu \text{M} \) \(^{13}\). In addition, amitriptyline N-demethylation is mediated by CYP3A4, CYP1A2, CYP2D6, and CYP2C9 \(^{16}\). It is also reported that amoxapine is metabolized to 7-hydroxyamoxapine and 8-hydroxyamoxapine \(^{2,22}\), however there is not much information about the corresponding enzyme mediating this biotransformation. The data presented here showed that amoxapine inhibits the CYP2D6 and CYP3A4 enzymes competitively. The major metabolic pathway converting amoxapine to 7- or 8- hydroxyamoxapine is aromatic hydroxylation, as for other TCAs. Together with results from other studies, our results indicate that 7- or 8- hydroxylation of amoxapine may be catalyzed mainly by CYP2D6 and partially by CYP3A4.

It has been reported that TCAs are metabolized by several CYP isozymes \(^{13-19}\) and also that several drug-drug interaction between TCAs and co-administered medicine occur \(^{20,21,23-25}\). Bergstom et al. \(^{23}\) reported that fluoxetine had potently lowered the systemic clearance of imipramine by 1/10. Another report showed that paroxetine administration prolongs the elimination half life of imipramine by approximately 50\% \(^{21}\). Inhibition of CYP enzyme activity by TCA has also been reported, particularly for CYP2D6, with apparent Ki values as follows: clomipramine (2.2 \( \mu \text{M} \)), desipramine (2.3 \( \mu \text{M} \)) and
amitriptyline (4.0 \mu M)^{26}. Shin et al. also reported that CYP2D6 activity was inhibited by amitriptyline, imipramine, nortriptyline and desipramine with apparent Ki values of 31.0, 28.6, 7.9 and 12.5 \mu M, respectively^{27}. Based on these previous studies, the apparent Ki value of amoxapine obtained from the present study is consistent with other TCAs, suggesting an inhibitory effect on CYP2D6-mediated drug metabolism.

Since TCAs inhibit CYP2D6-mediated enzyme activity^{26,27}, it is not surprising that numerous interactions between TCAs and commonly used drugs, which are categorized as substrates of CYP2D6, has been observed. However, the exact inhibitory potency of TCAs on CYP2D6 has not been extensively studied. It has been reported that fluoxetine and paroxetine, which are SSRIs, also inhibit CYP2D6 activity in vivo^{21,23,28} and in vitro^{26}, with Ki values of 0.6 and 0.15 \mu M, respectively. These Ki values are lower than the Ki values of TCAs described above. Furthermore, fluoxetine and paroxetine are widely distributed throughout body tissues^{21,29}, and have a Cmax level of approximately 160^{29} and 40 nM^{21}, respectively. These blood concentrations are close to their apparent Ki values estimated in vitro. In contrast, imipramine, which also is widely distributed throughout body tissue (Vd value=28–61 l/kg), has a Cmax value of approximately 70 nM^{21}, which is lower than the Ki value calculated from in vitro studies. Although it is hard to extrapolate these data directly to in vivo drug-drug interactions, imipramine probably does not affect the metabolism of the substrate of CYP2D6.

Amoxapine has been widely prescribed to patients with depression for a long time. However, there is scarce data on the drug-drug interactions between amoxapine and co-administrated medicines. Amoxapine is usually administered orally with a dose regimen of 25–75 mg daily in Japan. In serious patients, the dosage may be increased up to 300 mg daily^{23}. Amoxapine is widely distributed throughout all tissues of the body^{2,22}. Greenblatt et al reported that the concentration of amoxapine in tissue was 10 times higher than the plasma concentration 5 min after the intravenous administration in animal experiments^{30}. Amoxapine reached maximal serum levels of 0.14 \mu M between 1 and 1.5 hr after a single oral dosage (50 mg)^{2,22}. Similar to other TCAs, amoxapine takes several weeks to have a therapeutic effect. During this long-term period, accumulation of amoxapine in the body tissues may occur. However, the apparent Ki values of amoxapine for CYP2D6 and CYP3A4 estimated in the present study were higher than the drug concentration in plasma commonly using for the treatment of psychotic depression. Therefore, these results indicate that amoxapine might not inhibit the CYP2D6 and CYP3A4 enzyme-mediated drug metabolism of the co-administered medicines in vivo.

On the other hand, it has been reported that amoxapine is metabolized to the major metabolites, 7-hydroxyamoxapine and 8-hydroxyamoxapine in the liver^{2,22}. These metabolites have pharmacological effects similar to amoxapine^{2,22}. The active metabolite, 8-hydroxyamoxapine appears immediately in plasma and is eliminated quite slowly from the blood, with an average elimination half-life of 30.8 hr^{22}. We proposed that these metabolites might have an influence on the CYP enzyme-mediated drug metabolism. Unfortunately, it is impossible to obtain these metabolites. Therefore, we tried a pre-incubation study to evaluate the effects of these metabolites on CYP enzyme activity. The inhibitory potency of amoxapine was not increased by pre-incubation with or without NADPH. This result suggested that amoxapine metabolites do not affect the CYP enzyme-mediated drug metabolism. However, the technique used could not adequately represent the production of
amoxapine metabolites in vivo in type or amount, and further study will be needed to properly assess the effect of active metabolites on CYP enzyme activity.

In conclusion, amoxapine inhibits the catalytic activity of CYP2D6 and CYP3A4 in a competitive manner. The inhibitory potency of amoxapine on CYP2D6 was comparable to the other first-generation TCAs reported previously\(^{26,27}\), indicating that CYP2D6 may be involved in amoxapine metabolism. In addition, amoxapine metabolism may be inhibited by the drugs administered concurrently, which are metabolized by the CYP2D6 enzyme. However, comparison of the Ki values observed in this study and the therapeutic amoxapine concentration in the blood suggests that amoxapine would not inhibit the metabolism of co-administered medicines.

References

18) Brachtendorf L, Jetter A, Beckurts KT, Holscher AH and Fuhr U : Cytochrome P-450 enzymes contributing


